$FBIO News

Journey Medical (DERM) Stock Draws Fresh Price Target Split After Fortress Valuation Changes

Fortress Biotech to Participate in A.G.P.’s Annual Virtual Healthcare Conference

Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Fortress Biotech Q1 EPS $2.82 Beats $(0.22) Estimate, Sales $16.038M Miss $16.338M Estimate

Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™

Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights

Fortress Biotech Q4 EPS $(0.30) Beats $(0.42) Estimate, Sales $16.079M Miss $21.018M Estimate

Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million

Fortress Biotech And Cyprium Therapeutics Announce The Closing Of The Sale Of Cyprium's Rare Pediatric Disease Priority Review Voucher For Gross Proceeds Of $205M

Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026

Fortress Biotech’s Cyprium enters agreement to sell PRV for $205M

UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

HC Wainwright & Co. Reiterates Buy on Fortress Biotech, Maintains $17 Price Target

Fortress Biotech Subsidiary Cyprium Therapeutics To Sell Rare Pediatric Disease Priority Review Voucher For $205M

Fortress Biotech: The PRV Catalyst That Could Reprice This Microcap

Fortress Biotech, Inc. (NASDAQ:FBIO) Could Be Less Than A Year Away From Profitability

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States